The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
With so many weight loss medications on the market, it's easy to feel overwhelmed by the options. From brand-name heavy ...
With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...
One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...
Why digital measurements startup Koneksa Health thinks it can help pharma measure if their drugs are effective in people with ...
Weight-loss drugs could be a boon for insurers, but it is too soon to tell whether the industry will be transformed, the head ...
S&P 500, JPMorgan Chase & Co, Eli Lilly and Company, Novo Nordisk A/S Class B. Read Edison Group (Melanie Jenner)'s latest article on Investing.com UK.
The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist obesity medications.
The Commonwealth Fund 2024 Biennial Health Insurance Survey found that 8 percent of Americans had no health insurance in 2023. It also found that 3 in 5 underinsured adults said they avoided care ...
In a report released today, Peter Welford from Jefferies maintained a Sell rating on Novo Nordisk (0QIU – Research Report). The company’s ...
Eli Lilly & Co. will begin studies to see if its blockbuster weight-loss medicines are also effective at controlling addictive behaviors like alcohol abuse, smoking and drug addiction, Chief Executive ...